Congress legalizes cheaper drug imports to break pharma pricing power

What it does

This bill legalizes the importation of prescription drugs into the United States by pharmacies, wholesale distributors, and individuals from Canada, the UK, EU member states, and Switzerland—countries with FDA-recognized drug safety standards. It requires the FDA to certify foreign pharmacies and distributors, establish a fee-based registration system, and enforce rules against drug manufacturers who try to block or price-discriminate against importers. The bill aims to lower drug costs for Americans by allowing access to the same medications sold legally abroad at significantly lower prices.

Why we flagged it

The bill's core mechanism is deregulatory—it removes a legal prohibition—but the operative intent is not deregulation for its own sake; it is price transparency and consumer access. The bill simultaneously imposes new regulatory requirements (FDA certification, testing, reporting) and restricts manufacturer conduct (anti-discrimination rules). The character is best described as a structural reform that legalizes a market mechanism (parallel trade) to expose and constrain artificial price differe

What the text implies

• Manufacturers may respond by refusing to sell to foreign pharmacies or by creating different formulations for different markets, triggering enforcement actions and litigation that could delay implementation.
• The bill's expansion authority (subsection e) allows the Secretary to add countries beyond the initial four if safety is demonstrated, potentially opening importation from lower-cost jurisdictions with weaker regulatory standards—the criteria are safety-focused but implementation discretion is broad.
• Biannual reporting requirements (subsection j) create a new data stream on drug pricing and sourcing that will expose price discrimination by manufacturers; this transparency may trigger political pressure for price regulation or international trade disputes.
• Individual importation (subsection d(2)) is capped at 90-day supplies for personal use, but enforcement discretion (subsection i) is delegated to the Secretary, creating uncertainty about what constitutes 'personal use' and potential for inconsistent enforcement.
• The bill does not address patent law or exclusivity periods; manufacturers can still block generic competition in the U.S. while selling cheaper versions abroad, meaning importation relief is temporary unless patent/exclusivity rules change.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary Americans gain direct access to lower-cost medications legally available in peer nations, addressing a documented crisis in which tens of millions skip prescriptions due to cost. The bill preserves FDA safety oversight through certification of foreign sellers and ongoing testing, and includes enforcement mechanisms against counterfeit drugs and supply manipulation by manufacturers.

Who stands to gain

• consumers and patients (lower out-of-pocket drug costs)
• foreign pharmacies and wholesale distributors (new market access and certification fees)
• generic drug manufacturers and biosimilar makers (potential new distribution channels)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), Canada, United Kingdom, European Union, Switzerland, OECD (Organisation for Economic Co-operation and Development), Pharmaceutical manufacturers, Licensed foreign pharmacies, Foreign wholesale distributors, U.S. wholesale distributors and pharmacies, GAO (Government Accountability Office)

Where it stands

9 cosponsors: 9 Democrats.

• May 1, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 1, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $175,000 in lobbying spend. A filing names 43 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Jan Schakowsky, the sponsor, reported $88,051 in PAC receipts in the 2026 cycle.

• Alliance for Retired Americans — $175,000 on 2 filings

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.